These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 28687071

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Leishmaniasis in immunosuppressed individuals.
    van Griensven J, Carrillo E, López-Vélez R, Lynen L, Moreno J.
    Clin Microbiol Infect; 2014 Apr; 20(4):286-99. PubMed ID: 24450618
    [Abstract] [Full Text] [Related]

  • 6. A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure.
    Eichenberger A, Buechi AE, Neumayr A, Hatz C, Rauch A, Huguenot M, Diamantis-Karamitopoulou E, Staehelin C.
    BMC Infect Dis; 2017 Jan 17; 17(1):81. PubMed ID: 28095796
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D, Ramesh V, Verma S, Ramam M, Salotra P.
    Ann Trop Med Parasitol; 2009 Dec 17; 103(8):727-30. PubMed ID: 20030997
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.
    Lancet; 2011 Feb 05; 377(9764):477-86. PubMed ID: 21255828
    [Abstract] [Full Text] [Related]

  • 17. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S, Chakravarty J.
    Expert Opin Pharmacother; 2013 Jan 05; 14(1):53-63. PubMed ID: 23256501
    [Abstract] [Full Text] [Related]

  • 18. Comparison of in vitro Resistance of Wild Leishmania İsolates, Which are Resistant to Pentavalent Antimonial Compounds, Against Drugs Used in the Treatment of Leishmaniasis.
    Özbilgin A, Çavuş İ, Kaya T, Yıldırım A, Harman M.
    Turkiye Parazitol Derg; 2020 Mar 20; 44(1):12-16. PubMed ID: 32212583
    [Abstract] [Full Text] [Related]

  • 19. The treatment of visceral leishmaniasis: safety and efficacy.
    Jha RK, Sah AK, Shah DK, Sah P.
    JNMA J Nepal Med Assoc; 2013 Mar 20; 52(192):645-51. PubMed ID: 25327244
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.